Timothy B. Lowinger
2019
In 2019, Timothy B. Lowinger earned a total compensation of $873.4K as Chief Science and Technology Officer at Mersana Therapeutics, a 17% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $173,140 |
|---|---|
| Option Awards | $139,764 |
| Salary | $393,500 |
| Stock Awards | $160,000 |
| Other | $7,000 |
| Total | $873,404 |
Lowinger received $393.5K in salary, accounting for 45% of the total pay in 2019.
Lowinger also received $173.1K in non-equity incentive plan, $139.8K in option awards, $160K in stock awards and $7K in other compensation.
Rankings
In 2019, Timothy B. Lowinger's compensation ranked 9,865th out of 13,971 executives tracked by ExecPay. In other words, Lowinger earned more than 29.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,865 out of 13,971 | 29th |
Division Manufacturing | 3,981 out of 5,695 | 30th |
Major group Chemicals And Allied Products | 1,515 out of 2,194 | 31st |
Industry group Drugs | 1,295 out of 1,880 | 31st |
Industry Pharmaceutical Preparations | 962 out of 1,392 | 31st |
Source: SEC filing on April 27, 2021.
Lowinger's colleagues
We found four more compensation records of executives who worked with Timothy B. Lowinger at Mersana Therapeutics in 2019.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Mersana Therapeutics CEO Anna Protopapas' 2022 pay falls 66% to $2.8M
April 28, 2023
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020
Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
April 23, 2019